A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer

Trial Profile

A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Emibetuzumab (Primary) ; Ramucirumab
  • Indications Adenocarcinoma; Gastric cancer; Liver cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 28 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top